Glucotrack, INC

Glucotrack, Inc. has received notice from Nasdaq of its intent to delist the company's securities due to failure to meet the minimum bid price requirement, with trading suspension set for October 30, 2026.

Glucotrack, Inc. has implemented a 1-for-2 reverse stock split, effective October 23, 2026, and has completed its merger with Lokahi Therapeutics Inc., with pro forma financial information reflecting combined operations.

Glucotrack, Inc. has issued $2.56 million in senior secured convertible promissory notes for $2 million cash, reflecting a 22% original issue discount, alongside warrants for additional shares.

Glucotrack, Inc. has entered into a Waiver Agreement, leading to the issuance of new warrants and modification of terms for existing ones, impacting potential future share dilution and exercise price adjustments.

Glucotrack, Inc. files an amendment to its 8-K to update pro forma financials reflecting its merger with Lokahi Therapeutics and a 1-for-15 reverse stock split.

Glucotrack, Inc. has amended its common stock purchase warrants to comply with Nasdaq listing requirements, adjusting floor prices and anti-dilution provisions.

GlucoTrack reports Q1 2026 results amid going concern warnings and a pending Nasdaq delisting appeal.

Glucotrack, Inc. reported an increased net loss for Q3 2025, alongside positive first-in-human clinical trial results for its implantable continuous blood glucose monitor and ongoing efforts to secure future financing.

Glucotrack, Inc. reported progress in its implantable glucose monitor clinical trials and significant capital raises, but disclosed substantial doubt about its ability to continue as a going concern and identified material weaknesses in internal controls.

GlucoTrack Inc. announces its financial results for the first quarter of 2025, showcasing advancements in its Glucotrack CBGM development and ongoing efforts to secure funding.

GlucoTrack Inc. reported a net loss of $5.1 million for the third quarter of 2024, as it continues to develop its implantable continuous glucose monitor (CGM) technology.

Glucotrack Inc. reported its financial results for the second quarter of 2024, highlighting a significant increase in research and development expenses as it advances its implantable continuous glucose monitoring (CGM) technology.

Glucotrack, Inc. reports progress on its implantable continuous blood glucose monitor and recent financing, but faces substantial doubt about its ability to continue as a going concern and ongoing Nasdaq listing challenges.

Glucotrack Inc.'s latest 10-K filing highlights the company's focus on developing its implantable continuous blood glucose monitor (CBGM) while navigating financial uncertainties and Nasdaq compliance.

GlucoTrack, Inc.'s 2023 annual report highlights a strategic shift towards implantable continuous glucose monitoring (CGM) technology, alongside ongoing financial losses and concerns about the company's ability to continue as a going concern.

Glucotrack, Inc. has filed an amendment to its Form 8-K, providing updated pro forma financial statements reflecting its merger with Lokahi Therapeutics Inc. and a subsequent 1-for-15 reverse stock split.

Glucotrack, Inc. (operating as Lkahi Therapeutics) provided a strategic update on its LT-100 development program for osteoarthritis, AI platform expansion, and clinical priorities.

Glucotrack, Inc. filed an amendment to its Form 8-K to include financial statements for Lokahi Therapeutics Inc. following a reverse merger, revealing a significant increase in Lokahi's net loss and ongoing going concern issues.

Glucotrack, Inc. and Lokahi Therapeutics have completed a strategic business combination, creating a publicly listed platform for healthcare asset identification and advancement.

Glucotrack, Inc. Director Andrew K. Balo increased his beneficial ownership of common stock and stock options, following multiple reverse stock splits by the company.

Glucotrack, Inc. Director Luis Malave reported acquiring additional common stock and stock options, increasing his beneficial ownership.

Glucotrack, Inc. is holding a special meeting on September 11, 2026, to seek shareholder approval for significant stock issuances related to financing agreements, which may result in substantial dilution.

Glucotrack, Inc. announced its 2026 Annual Meeting of Stockholders, scheduled for August 18, 2026, to address key proposals including director elections, executive compensation, auditor ratification, a reverse stock split, and a warrant inducement.

Glucotrack, Inc. calls a Special Meeting to approve significant stock issuances for capital raises and ratify its independent auditor.

Glucotrack, Inc.'s special meeting of stockholders was permanently adjourned and cancelled after failing to achieve a quorum on two separate occasions.

Glucotrack, Inc. reconvenes its Special Meeting of Shareholders on November 7, 2025, to vote on a $20 million Equity Purchase Agreement with Sixth Borough Capital Fund LP.

Glucotrack, Inc. announced the adjournment of its Special Meeting of Stockholders from October 31, 2025, to November 7, 2025, with no changes to the record date or proposals.

Glucotrack, Inc. has filed an amended registration statement detailing the potential resale of over 43 million shares of common stock, highlighting ongoing financial challenges and Nasdaq listing concerns.

Glucotrack, Inc. filed an S-1/A to register shares for resale under a new $20.0 million committed equity financing facility, while detailing significant progress in its implantable glucose monitor development and ongoing Nasdaq listing challenges.

Glucotrack, Inc. has entered into a $20 million committed equity financing agreement with Sixth Borough Capital Fund, LP, while progressing its implantable continuous blood glucose monitor through human trials and addressing Nasdaq listing compliance.

GlucoTrack, Inc. files an amendment to its Form S-1 registration statement, primarily to include an updated legal opinion regarding the shares, warrants, and related securities being offered.

Glucotrack aims to raise up to $30 million by offering common stock, pre-funded warrants, and common stock purchase warrants.

Glucotrack, Inc. announces a proposed offering of common stock, pre-funded warrants, and common warrants to raise capital for general corporate purposes.

A Schedule 13G filing reveals Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri collectively hold a 9.99% stake in Glucotrack, Inc., acquired through convertible notes.

White Lion Capital LLC has reported beneficial ownership of 9.99% of Glucotrack, Inc.'s common stock, primarily through existing holdings and potential future acquisitions via various agreements.

Armistice Capital, LLC and Steven Boyd have jointly reported beneficial ownership of 102,115 shares, representing 4.99% of GlucoTrack, Inc.'s common stock, as of March 31, 2026.

Sabby Management, LLC, Sabby Volatility Warrant Master Fund LTD, and Hal Mintz have jointly disclosed a passive ownership of 4.9% of Glucotrack, Inc.'s common stock.